(3.237.20.246) 您好!臺灣時間:2021/04/16 07:37
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:劉香爾
研究生(外文):Hsiang-Erh Liu
論文名稱:探討Dynasore在人類肋膜間皮細胞影響第一型胞漿素原活化抑制劑表現及基質金屬蛋白酵素活化之機制
論文名稱(外文):The Effect of Dynasore on Plasminogen Activator Inhibitor-1 Expression and Matrix Metalloproteinases Activation in Human Pleural Mesothelial Cells
指導教授:蕭哲志蕭哲志引用關係
學位類別:碩士
校院名稱:臺北醫學大學
系所名稱:藥理學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2007
畢業學年度:95
語文別:中文
論文頁數:83
中文關鍵詞:肋膜間皮細胞第一型胞漿素原活化抑制劑
外文關鍵詞:pleural mesothelial cellsplasminogen activator inhibitor-1dynasore
相關次數:
  • 被引用被引用:0
  • 點閱點閱:84
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
第一型胞漿素原活化抑制劑(plasminogen activator inhibitor-1, PAI-1)為體內調控胞漿素原活化劑(plasminogen activator)之主要因子,在體內血栓及纖維蛋白溶解系統的平衡調節中扮演重要的角色。許多疾病狀態下都能發現不正常的PAI-1表現,例如:粥狀動脈硬化、敗血症、腎臟與肺部纖維化等疾病。根據文獻顯示,人類肋膜間皮細胞(human pleural mesothelial cells)與其他發炎細胞大量合成與釋放PAI-1會影響肋膜損傷後的再生修復並促使肋膜纖維化。
本研究利用人類肋膜間皮細胞株MeT-5A探討一種細胞穿透性dynamin抑制劑dynasore對PAI-1蛋白質表現之作用。實驗結果顯示,dynasore能夠分別抑制由TGF-beta1與TNF-alpha所誘導之基質金屬蛋白酵素(matrix metalloproteinase, MMP) MMP-2或MMP-9之酵素活性,且能加強由兩者所誘發之PAI-1蛋白質表現。而單獨投予dynasore,能夠誘導MeT-5A細胞PAI-1蛋白質與mRNA表現,但對於尿激酶型胞漿素原活化劑(urokinase-type plasminogen activator, uPA)之蛋白質與mRNA表現不具影響性,其中dynasore對於PAI-1表現之誘導作用可能與JNK及Smad訊息路徑有關。根據此實驗結果,初步認為dynasore可能藉由PAI-1之表現促進纖維化作用之進行,且對於細胞外基質蛋白分解酵素(extracellular matrix degrading proteases) MMP之活性有抑制性作用。此成分不僅具有成為肋膜黏連劑(pleurodesing agent)之潛力,也可提供肋膜纖維化疾病相關研究一個新的方向,因此往後可進一步探討其詳細分子作用機制,並利用肋膜積液之動物模式探討其促肋膜黏連作用之實際可能性。
Plasminogen activator inhibitor-1 (PAI-1) is a primary regulator of plasminogen activation that plays an essential role in regulating physiological thrombotic/fibrinogic balance. Abnormal expression of PAI-1 has been reported in various types of human diseases, such as atherosclerosis, sepsis, renal and lung fibrosis. PAI-1 produced by human pleural mesothelial cells and other inflammatory cells may have an effect on tissue remodeling and promoting pleural fibrosis.
In this study, we examined the effects of dynasore, a cell-permeable inhibitor of dynamin, on PAI-1 expression and matrix metalloproteinases (MMPs) activation in human pleural mesothelial cell line (MeT-5A). The results indicate that dynasore inhibited the activation of MMP-2 and -9 induced by TGF-beta1 and TNF-alpha respectively. Furthermore, dynasore enhanced the stimulatory effects of TGF-beta1 and TNF-alpha on PAI-1 protein expression. On the other hand, dynasore upregulated PAI-1 expression in MeT-5A cells which may result from JNK and Smad signaling activation. According to the profibrotic effects of dynasore, we suggest that further studies on its molecular mechanisms and in vivo study may be conducted to see its possibility of being a potential pleurodesing agent.
縮寫表……………………………………………………2
中文摘要…………………………………………………3
英文摘要…………………………………………………4
壹、緒論
文獻回顧……………………………………………… 5
研究目的………………………………………………18
實驗設計………………………………………………19
貳、研究材料與方法
實驗材料………………………………………………20
實驗方法………………………………………………27
參、結果………………………………………………36
肆、討論………………………………………………45
伍、結論與展望………………………………………50
陸、附圖………………………………………………51
柒、圖表………………………………………………55
捌、參考文獻…………………………………………75
Alessi, M. C., Bastelica, D., Morange, P., Berthet, B., Leduc, I., Verdier, M., Geel, O., and Juhan-Vague, I. (2000). Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49, 1374-1380.

Blobe, G. C., Schiemann, W. P., and Lodish, H. F. (2000). Role of transforming growth factor beta in human disease. N Engl J Med 342, 1350-1358.

Boehm, J. R., Kutz, S. M., Sage, E. H., Staiano-Coico, L., and Higgins, P. J. (1999). Growth state-dependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor-beta 1. J Cell Physiol 181, 96-106.

Branton, M. H., and Kopp, J. B. (1999). TGF-beta and fibrosis. Microbes Infect 1, 1349-1132.

Brogren, H., Karlsson, L., Andersson, M., Wang, L., Erlinge, D., and Jern, S. (2004). Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 104, 3943-3948.

Brown, N. J., Kim, K. S., Chen, Y. Q., Blevins, L. S., Nadeau, J. H., Meranze, S. G., and Vaughan, D. E. (2000). Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85, 336-344.

Ceresa, B. P., and Schmid, S. L. (2000). Regulation of signal transduction by endocytosis. Curr Opin Cell Biol 12, 204-210.

Chen, Y. Q., Su, M., Walia, R. R., Hao, Q., Covington, J. W., and Vaughan, D. E. (1998). Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 273, 8225-8231.

Chorostowska-Wynimko, J., Skrzypczak-Jankun, E., and Jankun, J. (2004). Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis Int J Mol Med 13, 759-766.

Corbel, M., Belleguic, C., Boichot, E., and Lagente, V. (2002). Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol 18, 51-61.

Corbel, M., Boichot, E., and Lagente, V. (2000). Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury. Braz J Med Biol Res 33, 749-754.

Dennler, S., Itoh, S., Vivien, D., Ten Dijke, P., Huet, S., and Gauthier, J. M. (1998). Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17, 3091-3100.

Derynck, R., and Zhang, Y. E. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425, 577-584.

Di Guglielmo GM, L. R. C., Goodfellow AF, Wrana JL. (2003). Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 5, 410-421.

Dichek, D., and Quertermous, T. (1989). Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 74, 222-228.

Du, X. L., Edelstein, D., Rossetti, L., Fantus, I. G., Goldberg, H., Ziyadeh, F., Wu, J., and Brownlee, M. (2000). Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97, 12222-12226.

Eren, M., Painter, C. A., Gleaves, L. A., Schoenhard, J. A., Atkinson, J. B., Brown, N. J., and Vaughan, D. E. (2003). Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice. J Thromb Haemost 1, 2389-2396.

Eriksson, P., Nilsson, L., Karpe, F., and Hamsten, A. (1998). Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 18, 20-26.

Falk, P., Ma, C., Chegini, N., and Holmdahl, L. (2000). Differential regulation of mesothelial cells fibrinolysis by transforming growth factor beta 1. Scan J Clin Lab Invest 60, 439-447.

Feener, E. P., Northrup, J. M., Aiello, L. P., and King, G. L. (1995). Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 95.

Felberbaum-Corti, M., Van Der Goot, F. G., and Gruenberg, J. (2003). Sliding doors: clathrin-coated pits or caveolae? Nat Cell Biol 5, 382-384.

Francis, C. W. (2002). Plasminogen activator inhibitor-1 levels and polymorphisms. Arch Pathol Lab Med 126, 1401-1404.

Gershtein, E. S., and Kushlinskii, N. E. (2001). Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Bull Exp Biol Med 131, 67-72.

Ginsburg, D., Zeheb, R., Yang, A. Y., Rafferty, U. M., Andreasen, P. A., Nielsen, L., Dano, K., Lebo, R. V., and Gelehrter, T. D. (1986). cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 78, 1673-1680.

Hou, B., Eren, M., Painter, C. A., Covington, J. W., Dixon, J. D., Schoenhard, J. A., and Vaughan, D. E. (2004). Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem 279, 18127-18136.

Huggins, J. T., and Sahn, S. A. (2004). Causes and management of pleural fibrosis. Respirology 9, 441-447.

Idell, S., Zweib, C., Kumar, A., Koenig, K. B., and Johnson, A. R. (1992). Pathways of fibrin turnover of human pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 7, 414-426.

Kanalas, J. J., and Hopfer, U. (1997). Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells. J Am Soc Nephrol 8, 184-192.

Klinger, K. W., Winqvist, R., Riccio, A., Andreasen, P. A., Sartorio, R., Nielsen, L. S., Stuart, N., Stanislovitis, P., Watkins, P., Douglas, R., and et al. (1987). Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 84, 8548-8552.

Lakhiaev, A. V., Nalian, A., Koenig, K. B., and Idell, S. (2007). Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis. Thromb Res [Epub ahead of print].

Lee, C. C., and Huang, T. S. (2005). Plasminogen activator inhibitor-1: the expression, biological functions, and effects on tumorigenesis and tumor cell adhesion and migration. J Cancer Mol 1, 25-36.

Lee, Y. C., and Lane, K. B. (2001). The many faces of transforming growth factor-beta in pleural diseases. Curr Opin Pulm Med 7, 173-179.

Light, R. W., and Lee, Y. C. (2003). Textbook of Pleural Diseases, 1st edn (London: Arnold).

Lijnen, H. R. (2005). Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3, 35-45.

Lijnen, H. R., and Collen, D. (1997). Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis 39, 343-350.

Ma, C., Tarnuzzer, R. W., and Chegini, N. (1999). Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor-b1. Wound Repair Regen 7, 477-485.

Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C., and Kirchhausen, T. (2006). Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 10, 839-850.

Margaglione, M., Grandone, E., Vecchione, G., Cappucci, G., Giuliani, N., Colaizzo, D., Celentano, E., Panico, S., and Di Minno, G. (1997). Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol 17, 2082-2087.

Martin-Chouly, C. A., Astier, A., Jacob, C., Pruniaux, M. P., Bertrand, C., and Lagente, V. (2004). Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci 75, 823-840.

Miyazono, K. (2000). Positive and negative regulation of TGF-beta signaling. J Cell Sci 113, 1101-1109.

Morange, P. E., Henry, M., Tregouet, D., Granel, B., Aillaud, M. F., Alessi, M. C., and Juhan-Vague, I. (2000). The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 20, 1387-1391.

Murphy, G., Stanton, H., Cowell, S., Butler, G., Knauper, V., Atkinson, S., and Gavrilovic, J. (1999). Mechanisms for pro-matrix metalloproteinase activation. APMIS 107, 38-44.

Mutsaers, S. E. (2002). Mesothelial cells: their structure, function and role in serosal repair. Respirology 7, 171-191.

Mutsaers, S. E., Prele, C. M., Brody, A. R., and Idell, S. (2004). Pathogenesis of pleural fibrosis. Respirology 9, 428-440.

Nagase, H., Visse, R., and Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69, 562-573.

Nakamura, S., Nakamura, I., Ma, L., Vaughan, D. E., and Fogo, A. B. (2000). Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type I receptor in vivo. Kidney Int 58, 251-259.

Neragi-Miandoab, S. (2006). Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 54, 1-9.

Newton, A. J., Kirchhausen, T., and Murthy, V. N. (2006). Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis. Proc Natl Acad Sci U S A 103, 17955-17960.

Peraldi, M. N., Rondeau, E., Medcalf, R. L., Hagege, J., Lacave, R., Delarue, F., Schleuning, W. D., and Sraer, J. D. (1992). Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells. Biochim Biophys Acta 1134, 189-196.

Pillay, V., Dass, C. R., and Choong, P. F. (2007). The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25, 33-39.

Rerolle, J. P., Hertig, A., Nguyen, G., Sraer, J. D., and Rondeau, E. P. (2000). Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 58, 1841-1850.

Robertson, S. E., Setty, S. R., Sitaram, A., Marks, M. S., Lewis, R. E., and Chou, M. M. (2006). Extracellular signal-regulated kinase regulates clathrin-independent endosomal trafficking. Mol Biol Cell 17, 645-657.

Rougier, J. P., Moullier, P., and Piedaguel, R. (1997). Hyperosmolality suppresses but TGF beta1 increases MMP9 in human peritoneal mesothelial cells. Kidney Int 51, 337-347.

Sahni, A., and Francis, C. W. (2003). Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2. J Thromb Haemost 1, 1271-1277.

Shiou, S. R., Datta, P. K., Dhawan, P., Law, B. K., Yingling, J. M., Dixon, D. A., and Beauchamp, R. D. (2006). Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta. J Biol Chem 281, 33971-33981.

Sidenlus, N., and Blasi, F. (2003). The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22, 205-222.

Smith, L. H., Coats, S. R., Qin, H., Petrie, M. S., Covington, J. W., Su, M., Eren, M., and Vaughan, D. E. (2004). Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor a and estrogen receptor b in endothelial cells. Circ Res 95, 269-275.

Strandberg, L., Lawrence, D., and Ny, T. (1988). The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 176, 609-616.

Strickland, S. (2001). Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost 86, 138-143.

ten Dijke, P., and Hill, C. S. (2004). New insights into TGF-beta-Smad signaling. Trends Biochem Sci 29, 265-273.

Thompson, H. M., and McNiven, M. A. (2006). Discovery of a new ''dynasore''. Nat Chem Biol 2, 355-356.

Travis, J., and Salvesen, G. S. (1983). Human plasma proteinase inhibitors. Annu Rev Biochem 52, 655-709.

Tsikouris, J. P., Suarez, J. A., and Meyerrose, G. E. (2002). Plasminogen activator inhibitor-1: physiology role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol 42, 1187-1199.

Vaughan, D. E. (2005). PAI-1 and atherothrombosis. J Thromb Haemost 3, 1879-1883.

Vaughan, D. E., Lazos, S. A., and Tong, K. (1995). Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95, 995-1001.

Wang, L. H., Rothberg, K. G., and Anderson, R. G. (1993). Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 123, 1107-1117.

Westermarck, J., and Kahari, V. M. (1999). Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13, 781-792.

Wileman, S. M., Booth, N. A., Moore, N., Redmill, B., Forrester, J. V., and Knott, R. M. (2000). Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells. Br J Ophthalmol 84, 417-422.

Wilson, H. M., Reid, F. J., Brown, P. A., Power, D. A., Haiters, N. E., and Booth, N. A. (1993). Effect of transforming growth factor-beta 1 on plasminogen activators and plasminogen activator activator inhibitor-1 in renal glomerular cells. Exp Nephrol 1, 343-350.

Yamamoto, K., and Saito, H. (1998). A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 68, 371-385.

Yoshizawa, M., Miyazaki, H., and Kojima, S. (1998). Retinoids potentiate transforming growth factor-beta activity in bovine endothelial cells through up-regulating the expression of transforming growth factor-beta receptors. J Cell Physiol 176, 565-573.

Zhong, J., Gencay, M. M., Bubendorf, L., Burgess, J. K., Parson, H., Robinson, B. W., Tamm, M., Black, J. L., and Roth, M. (2006). ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol 207, 540-552.

Zhu, Z., Yao, J., Wang, F., and Xu, Q. (2002). TNF-alpha and the phenotypic transformation of human peritoneal mesothelial cell. Clin Med J (Engl) 115, 513-517.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關論文
 
1. 何艷宏(1995),「在全民健康保險制度下對商業性互補醫療險最適需求的決定模式」,《保險專刊》,42,頁119~137。
2. 朱澤民(2002),「全民健康保險財務收支發展及因應改革方案芻議—取消現行保險對象分類方式,以各類所得總額為計算保費之費基」,《主計月刊》,557,頁14~23。
3. 白明昭、陳靜雯、吳瓊華(2000),「民國八十五年觀察年度個人醫療保險與重大疾病保險經驗發生率探討」,《壽險季刊》,115,頁49~97。
4. 何艷宏(1996),「在全民健康保險制度下民眾對互補醫療險需求的模擬分析研究」,《保險專刊》,43,頁166~176。
5. 吳乾源(1998),「全民健保實施後對商業性保險之影響」,《復興學報》,民87.12,頁217~232。
6. 洪乙禎、譚令蒂、謝啟瑞(2005),「補充性健康保險與全民健保搭配的影響效果分析」,《經濟論文》,33(4),頁433~465。
7. 張加恩(1994),「加拿大全民健保借鏡」,《保險專刊》,35,頁102~105。
8. 紀駿輝(1997),「健康維護或降低財務風險?由兩種觀點來比較公營與自由市場的健康保險制度」,《公共衛生》,24(2),頁77~96。
9. 陳雲中(1992),「論全民健康保險與商業性健康保險之互補關係」,《保險專刊》,30,頁6~22。
10. 曾郁仁、王儷玲、何素蘭(1999),「風險趨避程度增加對市場保險與自我保險的需求分析」,《風險管理學報》,1(2),頁53~64。
11. 傅立葉(1995),「福利國家公/私部門的互動:台灣私人保險與社會保險關係的初步探討」,《中國社會學刊》,18,頁117~152。
12. 賴本隊(2005),「淺談健康險的經營」,《壽險季刊》,138,頁24~40。
13. 劉彩卿、陳欽賢、洪小喬(2004),「全民健保實施對商業健康保險購買決策的影響」,《財稅研究》,36(2),頁71~94。
 
1. 探討Carprofen及Caffeicacidphenethylester抑制LPS活化人類單核球細胞之作用機轉
2. 探討基質金屬蛋白酵素在cerulein引發急性胰臟炎中之活化
3. YC-1抑制腫瘤壞死因子對人類單核球細胞(THP-1)誘發第九型基質金屬酵素活性之探討
4. 穿心蓮內酯抑制人類血小板活化與凝集之分子機轉探討
5. Radicicol抑制內毒素誘發人類單核球細胞產生發炎細胞激素及基質金屬蛋白酶之機轉
6. 探討Caffeicacidphenethylester及Dynasore抑制微膠細胞活化之機轉及其於活體保護腦部發炎作用的效果
7. 探討N-hydroxycinnamoylphenalkylamides衍生物及AristolochicAcid抑制MCP-1誘發人類單核球細胞活化之作用機轉
8. 探討N-hydroxycinnamoylphenalkylamides衍生物抑制小膠質細胞活化之機轉及其於活體抗腦部發炎的效果
9. 探討Carbamazepine抑制脂多醣體刺激小膠質細胞產生誘發型一氧化氮合成酵素之作用
10. 探討N-hydroxycinnamoylphenalkylamides衍生物及Cinnamophilin抑制人類嗜中性白血球及單核球活化之作用機轉
11. 探討氧化態低密度脂蛋白與phenytoin對小膠質細胞產生誘發型一氧化氮合成酵素之影響
12. 防曬化妝品之天然物開發
13. 探討氧化膽固醇促進人類臍帶靜脈內皮細胞血管新生之作用與機轉
14. 探討比較YC-1等藥物對TGF-beta1刺激THP-1誘發MMP-2之抑制機轉
15. PMC與TMPZ於暫時性局部腦缺血與再灌流動物模式中神經保護作用之機轉探討
 
系統版面圖檔 系統版面圖檔